Cutaneous B cell Pseudolymphoma in a Psoriatic Patient Treated with Cyclosporine

Takahashi, Tomoko; Hata, M; Iwata, Hitoshi; Seishima, Mariko

doi:10.2340/00015555-2387

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Commonly implicated drugs include valproate, atenolol, griseofulvin, imatinib, angiotensinconverting enzyme inhibitors, allopurinol, cyclosporine, levofloxacin, antihistamines, SSRIs, and phenytoin. [45][46][47][48] Lesions can develop days, weeks, or even months after starting the culprit medication. 49 Medications are commonly associated with clonal or polyclonal reactions, adding to the diagnostic challenge of distinguishing the lesion from malignancy.…”

Section: Medicationsmentioning

confidence: 99%

“…Medications represent a major cause of B‐cell CLH. Commonly implicated drugs include valproate, atenolol, griseofulvin, imatinib, angiotensin‐converting enzyme inhibitors, allopurinol, cyclosporine, levofloxacin, antihistamines, SSRIs, and phenytoin 45–48 . Lesions can develop days, weeks, or even months after starting the culprit medication 49 .…”

Section: Reactive B‐cell Clhmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous reactive B‐cell lymphoid proliferations

Khalil

Donthi²,

Gru

2022

J Cutan Pathol

View full text Add to dashboard Cite

Cutaneous lymphoid hyperplasia (CLH), also known as cutaneous pseudolymphoma, is a spectrum of benign conditions characterized by reactive B‐ and T‐cell cutaneous lymphocytic infiltrates. B‐cell lymphoid proliferations are a heterogenous group of non‐neoplastic cutaneous diseases that must be histopathologically distinguished from cutaneous B‐cell lymphomas. These proliferations can be observed as reactive phenomena to infections, medications, allergens, neoplasms, and more. Furthermore, there are many inflammatory conditions that present with reactive B‐cell infiltrates, including actinic prurigo, Zoon balanitis, Rosai‐Dorfman disease, and cutaneous plasmacytosis. This review summarizes multiple cutaneous B‐cell lymphoid proliferations within the major categories of reactive and disease‐associated CLH. Further we discuss major discriminating features of atypical CLH and malignancy. Understanding the specific patterns of B‐cell CLH is essential for the proper diagnosis and treatment of patients presenting with such lesions.

show abstract